New insider activity at Eli Lilly & Co ( (LLY) ) has taken place on February 25, 2025.
Lilly Endowment Inc, a significant shareholder of Eli Lilly & Co, has recently sold 99,452 shares of the company’s stock, amounting to a substantial transaction worth $87,786,167.
Recent Updates on LLY stock
Eli Lilly & Co has been in the spotlight due to several key developments. The company is seeing promising results from its next-generation obesity drug, retatrutide, with trial participants experiencing significant weight loss, prompting dose adjustments. Additionally, Eli Lilly announced a global licensing agreement with OliX Pharmaceuticals to develop and commercialize a Phase 1 candidate targeting metabolic-associated steatohepatitis. The company also reported strong Q4 results, leading BofA to raise its price target for Eli Lilly, citing good earnings and a positive FY25 EPS guidance. Furthermore, the VIVID-2 study results for their Crohn’s disease treatment, Omvoh, showed sustained clinical and endoscopic outcomes, reinforcing confidence in their innovative pipeline and strategic growth initiatives.
More about Eli Lilly & Co
YTD Price Performance: 13.37%
Average Trading Volume: 3,600,414
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $828.4B